动脉粥样硬化斑块逆转的治疗和挑战教学文稿.pptVIP

动脉粥样硬化斑块逆转的治疗和挑战 ;动脉粥样硬化——伴随一生的风险;动脉粥样硬化累及全身血管床;;PAS 三联的组成;PAS疗法的理论基础;*;*;化学修饰;内皮损伤诱发血栓形成示意图;;Our study on PAS therapy 2008 -2011, CHD were selected by coronary angiography or coronary CTA. All cases were divided into two groups; control group 65 (AS) aspirin 100mg/d and , Atrovastatin 20mg/d . PAS group 85(APS) probucol, 0.5g/d, aspirin100mg/d and Atrovastatin 20mg /d. And all cases were followed up for 1 year, examined the coronary plaque reversal through Coronary angiography or coronary CTA ;AS group (65case) Comparison of vascular plaque stenosis before and after therapy （ x±s，mm）;PASgroup（84case） Comparison of vascular plaque stenosis before and after therapy （ x±s，mm ;Comparison of vascular plaque stenosis AS and PAS therapy （;;Probucol与他汀联合治疗对斑块稳定性的影响;probucol单用或与他汀联用均显著提高斑块稳定性; [research unit] Department of Cardiovascular Medicine, Osaka  University Graduate School of Medicine, Japan. 【 [study design] multi-centered, randomised, case-control study 410 patients with FH were randomisely grouped into probucol group (307 cases), non-probucol group (103 cases) Follow-up for 15 years (average), 20 years (maximum) Study time: 1984-2005 [indicators] cardiovascular events: include acute myocardial infarction, pectoris angina, heart failure, TIA or atherosclerosis induced peripheral arterial disease ;;Although PAS therapy brought us good prospectus. But we still have some problems to investigate. Such as: Why combination therapy of atorvastatin and antioxidants make effects in plaque reversal? what is the mechanism behind it? We believe reversal of atherosclerotic plaque is not a mystery. It needs our continuity and hard work ;*